The anaplastic lymphoma kinase (ALK) gene is characteristically translocated in Anaplastic Large Cell Lymphomas (ALCL) and the juxtaposion of the ALK gene to multiple partners results in its constitutive protein tyrosine kinase activity. We show here that expression of activated ALK induces the constitutive phosphorylation of Stat3 in transfected cells as well as in primary human ALCLs. Furthermore, immunohistochemical studies demonstrate that among distinct human B and T cell lymphomas, activation of Stat3 nuclear translocation is uniquely associated with ALK expression. NPM-ALK also binds and activates Jak3; however, Jak3 is not required for Stat3 activation or for cell transformation in vitro. Moreover, src family kinases are not necessary for NPM-ALK-mediated Stat3 activation or transformation, suggesting that Stat3 may be phosphorylated directly by ALK. To evaluate relevant targets of ALK-activated Stat3, we investigated the regulation of the anti-apoptotic protein Bcl-x L and its role in cell survival in NPM-ALK positive cells. NPM-ALK expression caused enhanced Bcl-x L transcription, largely mediated by Stat3. Increased expression of Bcl-x L provided sucient anti-apoptotic signals to protect cells from treatment with speci®c inhibitors of the Jaks/Stat pathway or the Brc-Abl kinase. These studies support a pathogenic mechanism whereby stimulation of anti-apoptotic signals through activation of Stat3 contributes to the successful outgrowth of ALK positive tumor cells.
Introduction
Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of malignancies representing the neoplastic clonal expansion of B or T lymphocytes transformed at dierent stages of dierentiation and maturation. Among the NHL, the CD30 positive Anaplastic Large Cell Lymphomas (ALCL) represent a distinct subset of neoplasms with unique morphological, immunophenotypical and clinical features (Harris et al., 1994) . ALCL include a distinct subset of tumors displaying chromosomal translocations involving the Anaplastic Lymphoma Kinase (ALK) (2p23;5q35) gene. Since the ®rst molecular characterization of the t(2;5)(2p23;5q35) translocation involving the nucleophosmin (NPM) and ALK genes (Morris et al., 1994) , several groups have identi®ed additional translocations in which ALK is fused to other partners including the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase/IMP cyclohydrolase (ATIC) and the clathrin heavy chain (CLTCL) genes (Drexler et al., 2000) . More recently, translocations juxtaposing the Translocation Promoter Region (TPR) to ALK were also found in approximately 50% of in¯ammatory myo®-broblastic tumors (Lawrence et al., 2000) .
The deregulated expression of ALK chimera allows the transformation of immortalized rodent cells and the escape of BaF3 cells from IL-3 dependence. All the chimeric ALK proteins have domains responsible for homo-dimerization, resulting in constitutive activation and phosphorylation of the ALK tyrosine kinase (Bischof et al., 1997) . However, the pathogenic mechanisms leading to ALK-mediated T-cell transformation remain unclear. Thus far, several signaling molecules have been shown to interact with NPM-ALK. These include Grb2, Shc, IRS-1, PLC-g and PI3K (Bai et al., 1998 (Bai et al., , 2000 Bischof et al., 1997; Fujimoto et al., 1996; Slupianek et al., 2001) . The pathogenic role of Shc and IRS-1 in ALK-mediated transformation has been excluded by mutagenesis studies (Fujimoto et al., 1996) , and the contribution of PLC-g remains controversial. For instance, while mutation of the PLC-g binding site (Y664A) rendered NPM-ALK unable to release transfected BaF3 cells from IL-3 dependency, truncated ALK proteins lacking residue 664 could eciently transform murine NIH3T3 ®broblasts (Bai et al., 1998) . In addition, we and others have recently shown that forced expression of ALK leads to the phosphorylation of AKT via PI3K. Moreover, and studies in vivo showed that NPM-ALK transformation is sensitive to inhibition by DNRas, suggesting that the Ras pathway is required for ALK-mediated transformation of Tlymphocytes.
Receptor tyrosine kinase (RTK) or fusion RTK proteins can activate multiple signaling pathways, including Ras, PI3K and Jak-Stat pathways. To study whether the constitutive expression of ALK fusion proteins leads to activation of the Jak and Stat proteins, we investigated their phosphorylation status after in vitro transfection and in fresh human ALCL tumors. Our ®ndings show that among the Jak-Stat molecules, only Jak3 and Stat3 are con- NPM-ALK and Stat3 expression vectors were cotransfected into h293T cells as indicated. The phosphorylation status of Stat3 was evaluated using a speci®c anti-pY-Stat3 antibody. CDK2 was used for normalization. (c) Stat3 is speci®cally upregulated by NPM-ALK. PC12 cells were transduced with VSG retroviral vectors carrying the wt or trunctated NPM-ALK (T498 and T526) constructs. These two truncated constructs were designed to maintain the catalytic domain and its activity but to lose the Shc and PLCg (T498) or PLCg (T526) binding sites, respectively. The death mutant K210R NPM-ALK was used as negative control. Cells were cultured for 36 h and subsequently lysed and immunoblotted with the indicated antibodies. (d) NPM-ALK leads to the upregulation of Stat3 mRNA transcripts. PC12 cells were transduced with the indicated retroviral vectors as above. Total RNA was extracted using a Triazol system (Sigma). cDNAs were subsequently ampli®ed with speci®c Stat3 oligoprimers for 30 cycles. Figure 1a ). To prove that Stat3 phosphorylation in ALCL-derived cell lines was directly related to the expression of NPM-ALK, we performed similar studies in h293T cells transfected with the full length NPM-ALK or ATIC-ALK (Drexler et al., 2000) fusion constructs and the kinase dead mutant, K210R NPM-ALK. The forced expression of functional ALK constructs, but not of the inactive form of NPM-ALK, led to the phosphorylation of Stat3 (Figure 1b) . Since the Western blot analysis demonstrated higher levels of endogenous Stat3 in ALK positive than in ALK negative cell lines (Figure 1a) , we investigated whether NPM-ALK could directly upregulate the expression of Stat3. Since ALK receptor is normally expressed only in neuronal cells (Iwahara et al., 1997; Morris et al., 1997) we decided to use the PC12 cells as a model. After the transduction of PC12 cells, we could demonstrate that the expression of functionally active NPM-ALK resulted in higher protein ( Figure 1c ) and mRNA levels (Figure 1d ) of Stat3. Taken together, these data suggest that ALK causes, in addition to Stat3 phosphorylation, enhanced transcription and/or stabilization of Stat3 mRNA levels, as well as increased levels of Stat3 protein in both PC12 and lymphoid cells.
To further explore the biological signi®cance of these ®ndings, we studied the phosphorylation status of Stat3 in a series of human ALK positive and negative lymphomas. Western blotting analysis showed that ALK positive, but not ALK negative, tumors displayed detectable levels of phosphorylated Stat3 (Figure 1e ). These observations were con®rmed by immunohistochemical analysis of a large number of human ALCLs and a representative panel of distinct B and T cell lymphoproliferative disorders as comparison. Since nuclear translocation of Stat proteins occurs following phosphorylation, the detection of Stat3 within the nucleus by immunohistochemistry was used to identify activated Stat3. In the majority of ALK positive lymphomas, Stat3 showed a nuclear staining in the tumor cells (Figure 1f ), whereas surrounding nonneoplastic lymphocytes were negative. In contrast, ALK negative cases showed primarily cytoplasmic Stat3 with only rare nuclear staining. Moreover, other groups of ALK-negative NHL only rarely contained a few tumor cells expressing nuclear Stat3 (Table 1) . Thus, Stat3 activation largely correlated with ALK expression in human lymphomas.
ALK positive tumors display phosphorylated Jak3 and do not require Src family members to stimulate Stat3 phosphorylation
To determine whether NPM-ALK activated Jak or Tyk2 proteins, we ®rst investigated the phosphorylation status of these molecules in human Karpas 299 and DHL (data not shown) ALK positive cell lines. Only Jak3 was found to be constitutively phosphorylated ( Figure 2a ). Furthermore, a series of immunoprecipitation experiments showed that Jak3 bound eciently to catalytically active NPM-ALK or T526NPM-ALK proteins but not to the kinase-dead mutant K210R NPM-ALK ( Figure 2b ). These ®ndings have been recently con®rmed in thymocytes derived from NPM-ALK transgenic mice (data not shown). To further identify a potential Jak3 docking site within NPM-ALK, a series of deletion constructs were generated and tested for their ability to bind Jak3 and/or to transform NIH3T3 cells. Interestingly, deletion of residues 118 ± 138 was sucient to abrogate Jak3 binding to ALK. Nevertheless, D118 ± 138 NPM-ALK still eciently induced Stat3 phosphorylation and transformed NIH3T3 cells (Figure 2c ), suggesting that Jak3 binding and activation was not essential for biological activity. To further validate this notion in lymphoid cells, we treated DHL and Karpas 299 tumor cells with AG490, a speci®c inhibitor of Jak enzymes. Figure 2 Characterization of Jak3 activation and Jak3-NPM-ALK interactions. (a) Jak-3 is constitutively activated in NPM-ALK. Total extracts (500 mg) from NPM-ALK Karpas 299 cells were immunoprecipitated with anti-Jak1, anti-Jak-2, anti-Tyk-2 and antiJak-3 Abs. The immunoprecipitates were analysed by immunoblotting with anti-pY Ab. The same membrane was subsequently stripped and blotted with anti-Jaks and anti-Tyk-2 antibodies (lower panels). The single band detected after immunoprecipitation with anti-Jak3 by the anti-pY antibody had the same molecular weight of the band detected by the speci®c anti-Jak3 antibody. (b) Phosphorylated Jak-3 binds to NPM-ALK. h293T cells were co-transfected with NPM-ALK, K210R NPM-ALK, D526NPM-ALK and Jak-3 constructs. After incubation for 36 h, cells were lysated and immunoprecipitated with a rabbit anti-ALK. NPM-ALK immunoprecipitates were subsequently subjected to immunoblotting with anti-pY, anti-Jak-3, and anti-ALK. (c) Schematic representation of trunctated NPM-ALK constructs. The NPM-ALK activation, the phosphorylation status of Stat3 and Jak3, and the transformation of NIH3T3 cells for each individual construct are indicated. The ALK and Jak-3 activation were detected by an immunoprecipitation-Western blotting assay using anti-ALK or anti-FLAG (T1-498, T1-458Y191F/Y445F, T1-436 and T1-363) or anti-Jak-3 antibodies for the immunoprecipitation and Western blotting with anti-pY antibody (Material and methods). Stat3 phosphorylation was documented by using a direct Western blotting and a speci®c anti-pY-Stat3 Ab. Transformation of NIH3T3 cells was evaluated documenting the presence of transformed foci as described in Material and methods. (d) ALK-mediated activation of Stat3 does not require Src, fyn and/or yes. MEF of wt and of SV40 transformed triple knockout Src/fyn/yes were infected with retroviral vectors carrying the mock vector (Pallino) or the NPM-ALK construct. Stat3 phosphorylation was studied by direct Western blotting. ALK and Src expression were evaluated using speci®c Abs. Notably, NPM-ALK expression was sensibly higher in the SYF7/7 cells. (e) the Src-family speci®c inhibitor PP2 does not change the phosphorylation levels of Stat3 in NPM-ALK positive ALCL cell lines. The ecacy of PP2 was ®rst documented studying the inhibition of the Src-mediated activation of Akt in COS-1 cells after treatment with EGF (upper panel). COS-1 cells were serum starved for 24 h and subsequently incubated with dierent concentration of PP2 for 2 h prior the treatment with EGF (10 min, 100 ng/ml, UBI). Phosphorylation levels of Akt were evaluated using an anti-Akt Ab (left upper panel). DHL ALCL cells were also incubated with 10 mg/ml or 50 mg/ml of PP2 for 2 h (right upper panel) and Stat3 phosphorylation levels were evaluated by direct Western. To study where longer exposure to PP2 could modulate the phosphorylation levels of Stat3, Karpas 299, DHL and JB cells were treated with 10 mg/ml of PP2 for 24 h (right bottom panel). Cellular lysated were blotted and Stat3 phosphorylation levels were tested as described. Total protein levels were normalized using an anti-b-tubulin Ab Oncogene NPM-ALK leads to Stat3 activation and Bcl-xL upregulation A Zamo et al Phosphorylation levels of Stat3 did not change following drug treatment (data not shown), con®rming that Jak catalytic activity is not required for Stat3 activation.
Interestingly, truncated and/or deleted constructs lacking¯anking sequences near and/or within the putative catalytic domain of ALK abolished its kinase activity and the transformation ability of the corresponding proteins (Figure 2c ). These ®ndings suggest the catalytic domain of ALK, determined by the analysis of the homology with the catalytic domains of known kinases (Morris et al., 1994) , is insucient and it requires additional¯anking regions possibly for the correct tridimensional folding of the protein. Src and src family members play crucial roles in signaling from RTK and are responsible for Stat activation under some circumstances (Wang et al., 2000) . To study whether NPM-ALK mediated activation of Stat3 required src, fyn or yes, the src family proteins expressed in ®broblasts, we examined Stat3 phosphorylation in mouse embryonal ®broblasts (MEFs) speci®cally deleted for all three src-related genes (Klinghoer et al., 1999) . As shown in Figure 2d , NPM-ALK-mediated Stat3 phosphorylation could be eciently achieved in the absence of all these kinases. Finally, to con®rm and extend these results in lymphoid cells, we investigated whether the phosphorylation of Stat3 of NPM-ALK positive cells could be modulated by PP2, a potent inhibitor of src kinases (Hanke et al., 1996) . The activity of PP2 was ®rst demonstrated by showing its ecacy in blocking srcmediated phosphorylation of Akt of COS-1 cells treated with EGF (Chen et al., 2001) . We subsequently used a high dose of PP2 (50 mM) for a short period of time (2 h) or an intermediate dose (10 mM) for a longer period of time (24 h; 50 mM PP2 were toxic when used for 24 h) to treat ALCL cells. Under both conditions all ALCL cell lines showed no changes in their Stat3 phosphorylation (Figure 2e, lower panel) . These ®ndings strongly argue that Stat3 phosphorylation levels in NPM-ALK positive cells do not require the activity of src.
The constitutive activation of Stat3 via ALK leads to Bcl-x L upregulation and protection from cell death Transcriptional activation of several genes has been implicated as targets for Stat3, including Cyclin D1, Bcl-x, p21 and c-myc (Bowman et al., 2000) . To study whether the expression of Stat3 regulated genes was also enhanced by ALK, we studied the activity of two Bcl-x L promoter constructs in the presence of NPM-ALK and K210R NPM-ALK. NPM-ALK, but not the kinase-dead mutant control, enhanced Bcl-x promoter activity, and this eect was completely blocked by Stat3b, a dominant negative form of Stat3 (Figure 3a ) (Catlett-Falcone et al., 1999) . To validate the biological signi®cance of these ®ndings, we investigated whether NPM-ALK could protect human U266 myeloma cells from cell death in the absence of cytokine signaling. The survival of U266 is largely dependent on an autocrine loop of secreted IL-6 that upregulates antiapoptotic signals via a Jak-Stat3 dependent-pathway. The treatment with AG490 blocks this Jak-Stat3 pathway and makes the U266 cells sensitive to spontaneous and to Fas-mediated apoptosis (CatlettFalcone et al., 1999) . Consistent with this model, treatment of control K210R NPM-ALK U266 cells with AG490 led to enhanced cell death. In contrast, NPM-ALK positive cells displayed signi®cantly lower apoptotic rates in the presence of the inhibitor. Both lines were equally resistant to Fas-mediated apoptosis in absence of AG490. Nonetheless, only NPM-ALK positive cells showed a greater resistance to Fasmediated apoptosis after the treatment with AG490 (Figure 3b ). These ®ndings strongly suggest that NPM-ALK anti-apoptotic signaling does not require Jak activation.
To explain the molecular mechanisms responsible for the ability of ALK to protect from cell death, we studied the expression of Bcl-x L protein and other known anti-apoptotic proteins. As expected, Bcl-x L protein levels substantially decreased in K210R NPM-ALK U266 after AG490 treatment. Conversely, Bcl-x L and survivin protein levels remained relatively higher in NPM-ALK positive cells. On the other hand, NPM-ALK expression did not signi®cantly modulate the protein levels of Bcl-2 and Mcl-1 (Figure 3c ).
To con®rm these ®ndings and to prove that these eects were not uniquely restricted to U266 cells, we tested the anti-apoptotic role of NPM-ALK in BcrAbl positive human acute leukemia K562 cells treated with the speci®c inhibitor of the Abl kinase, STI571 (Deininger et al., 1997) . Survival of K562 is dependent on the levels of anti-apoptotic signals that are largely mediated by the activity of the deregulated abl kinase, and may also involve activated Stats (Nieborowska-Skorska et al., 1999; Gesbert and Grin, 2000; Vigneri and Wang, 2001 ). K562 cells were transduced with K210R NPM-ALK-GFP and NPM-ALK-GFP viruses and then treated with STI571. Apoptotic cells were identi®ed using Annexin V staining. As shown, in Figure 4a , treatment with STI571 enhanced cell death of K210R NPM-ALK-GFP positive cells but not NPM-ALK-GFP cells ( Figure  4a ). Since the survival of K562 is dependent on activation of Bcl-x L through Stat5, which in turn depends on the tyrosine kinase activity of the BcrAbl fusion protein (Donato et al., 2001) , we also investigated the levels of Bcl-x L in transduced cells in the presence of STI571. As expected, STI571 blocked Stat5 phosphorylation and led to a decrease in Bcl-x L protein levels in control wt and K210R NPM-ALK cells (Figure 4b ). In NPM-ALK positive K562 cells, however, the presence of the inhibitor led to a similar downregulation of Stat5 phosphorylation but the cells maintained relatively high levels of Bcl-x L . It is likely that NPM-ALK sustained Stat3 phosphorylation, readily detectable only in NPM-ALK expressing cells (lanes 7 ± 9), was largely responsible for Bclx L expression (Bromberg et al., 1999) in the absence of Bcr-Abl catalytic function. 
Discussion
Cell transformation requires the acquisition of multiple genetic defects that ultimately lead to deregulated cell growth. Moreover, in addition to alterations that directly promote cell growth, neoplastic cells often acquire defects that protect tumor cells from cell death. In this study, we have demonstrated that the tyrosine kinase NPM-ALK responsible for ALCL malignancy causes constitutive activation of Stat3, which in turn promotes cell survival by inducing expression of the anti-apoptotic genes, Bcl-x L and survivin.
Translocations involving the ALK gene occur among NHLs exclusively in ALCL. The molecular mechanisms responsible for this exquisite speci®city are completely unknown and the molecular events leading to ALK mediated lymphoid transformation are still largely unclear. Several investigations have demonstrated that homodimerization of ALK chimeras results in constitutive activation of the tyrosine kinase (Bischof et al., 1997; Trinei et al., 2000) which is absolutely required for cell transformation (Drexler et al., 2000) . In vitro and in vivo studies have also shown that activated ALK ®res several signaling pathways, including PLCg and PI3K (Bai et al., 1998 (Bai et al., , 2000 . In this study, we have shown that human ALK positive ALCL lymphomas always display constitutively activated Stat3. Because Stat3 activation is largely restricted to ALK positive ALCLs, its detection oers a new diagnostic tool in the analysis of those tumors in which the identi®cation of ALK remains problematic. Moreover, we can speculate that the use of multiple markers could allow the identi®cation of new subsets of ALCLs with possibly unique clinical courses (Drexler et al., 2000) . Nieborowska-Skorska et al. The analysis of ALK positive cells has shown that NPM-ALK, in addition to promoting the phosphorylation of Stat3, also leads to increase Stat3 expression, enhancing the levels of Stat3 mRNA as a result of enhanced transcription or stabilization of the mRNA. Akira, (1999) have previously demonstrated that Stat3 levels are upregulated by IL-6 signaling, suggesting that a positive loop may be operational (Takeda et al., 1998) . A similar scenario may also occur in ALK positive cells.
Many molecules have been shown to have a role in the activation of Stats. Members of the Jak family have been demonstrated to be of crucial importance in many cases (Schlessinger, 2000) . In our study, we have found that Jak3 eciently binds to the active forms of NPM-ALK, suggesting that the kinase activity of the fusion protein is required for the docking of Jak3 to ALK. Since the region to which Jak3 binds to ALK does not display any canonical Jak binding sequence (118 ± 138 aa), we cannot exclude the possibility that an unknown adaptor molecule may also be involved in this interaction. Nevertheless, it appears that Jak3 activation is not strictly required for ALK mediated Stat3 activation, Bclx L upregulation and/or transformation. In fact, NPM-ALK can eciently transform ®broblast cells which do not express detectable Jak3 (i.e. NIH3T3 cells), and NPM-ALK mutants lacking the Jak3 binding site are still capable of inducing cell transformation as eciently as wild type NPM-ALK. Finally, the treatment of human ALCL cells with the Jak3 inhibitor AG490 did not produce any change in the phosphorylation status of Stat3. Nevertheless, we cannot exclude the possibility that Jak3 has other roles in lymphoid or non-lymphoid ALK positive tumors, perhaps independent of Stat3 (Lamant et al., 2000) . Similarly, src family kinases were Bcl-x L (32 kDa) protein levels after STI571 treatment. K562 transduced cells were incubated with STI571 (10 mM) or AG490 (50 mM) for 72 h. Protein expression was evaluated using speci®c antibodies by Western blotting not required for ALK-mediated Stat3 activation in ®broblasts. These data strongly suggest that ALK may activate Stat3 by direct phosphorylation. Nonetheless, the possibility that intermediate proteins might be involved cannot be totally excluded.
In the last few years, several genes have been demonstrated to be directly regulated by Stat3, among them dierent proteins that control cell cycle progression and cell survival (Bowman et al., 2000) . In this study we focused on the role of NPM-ALK activated Stat3 targets that could give tumor cells a biological advantage and contribute to their overall viability and ability to grow. Because a well established in vitro model enabling us to investigate the role of ALK and its relationship with the activation of Stat3 in T cells is not available, we have focused on two alternative systems in which cell survival largely depends on the activity of Stats. In the case of U266 cells, survival depends on an autocrine loop, IL6/ IL6R, leading to activation of Stat3 and upregulation of Bcl-x L (Catlett-Falcone et al., 1999) . Using this model we demonstrated that NPM-ALK can bypass the block imposed by the AG490 Jak kinase inhibitor, leading to maintenance of substantial levels of phosphorylated Stat3 which in turn upregulates the expression of Bcl-x L and survivin preventing cell death. Interestingly, NIH3T3 cells transformed by a constitutively active form of Stat3 display high levels of survivin (Shen et al., 2001) .
The validity of these ®ndings was also con®rmed using a dierent and alternative model taking advantage of K562 cells. Notably, these cells require Stat5 for their survival mediated by upregulation of Bcl-x L (Horita et al., 2000) . However, the forced expression of NPM-ALK was able to compensate for the loss of Bcr-Abl kinase activity due to the speci®c inhibitor of the BcrAbl kinase, STI571, maintaining cell survival, likely through activated Stat3. Similar and complementing data have been recently reported by two independent groups, demonstrating that NPM-ALK can upregulate phosphorylated Akt via PI3K, leading to survival of BaF3 cells (Bai et al., 2000; Slupianek et al., 2001) . However, we were unable to document any signi®cant change in the phosphorylated levels of Akt in our cell models. This discrepancy may be due to the overall levels of ALK in dierent cell types or to the fact that unique signaling pathways are operational in dierent cells. This notion is supported by the fact that in both U266 and K562, representing mature B cells and myeloid cells, Stat3 upregulation via ALK leads to the positive upregulation of Bcl-x L and survivin but not Mcl-1, a gene known to be positively regulated by Stat3. The mechanisms responsible for these cell type-speci®c phenomena are unclear and will require further investigation. Finally, the contribution(s) of other pathways ± including Erk1/2 ± in ALK-mediated survival and/or transformation are still largely undetermined. More studies are required to conclusively demonstrate that ALK elicits anti-apoptotic signals not only in B-and myeloid cells, but also in T cells, which represent the most common target cells of ALK translocations.
Material and methods

Pathological samples and antibodies
A panel of well-characterized Non-Hodgkin's lymphoma were retrieved from both the archives of the Hematopathology Laboratory of the New York University Medical Center and the Surgical Laboratory of the University of Torino and Verona, Italy. The lymphomas were classi®ed according to the international lymphoma study group, based on hematoxylin-eosin and immunoperoxidase stains, as previously described (Chiarle et al., 2000) . ALCL were characterized using a large panel of antibodies speci®cally recognizing Tcell and B-cell restricted antigens and ALK proteins (rabbit polyclonal, Zymed).
Immunohistochemical staining
Immunohistochemical stainings were performed on formalin ®xed paran embedded tissues using the avidin biotin peroxidase complex method and a semi-automated immunostainer (DAKO or Ventana System) as described (Chiarle et al., 2000) . Neoplasms were considered positive for Stat3 when a nuclear staining was detected in at least 25% of the tumor cells.
Cell lines and cell cultures
h293T, COS-1, PC12, U266, K562, Jurkat, Namalwa and Src, Yes and Fyn triple de®cient (SYF7/7) MEF cell lines were obtained from the American Tissue Culture Collection (ATCC). DHL, Karpas 299, and JB, were kindly provided by Dr Lorenzana. Transfections were performed with Eectene Reagent following the manufacturers' instructions (Qiagen). At least 1 mg of DNA was transfected in each transfection. After transfection (36 h), cells were washed and lysed.
Transduction experiments were performed using a VSV-G retroviral system (Clontech). Retroviruses were produced by co-transfecting 293GP cells (Clontech) with the GFP-Pallinobased (Grignani et al., 1998) retroviral vector (1 mg) and a VSV-G plasmid (1 mg) (Clontech).
Transformation assays were performed using NIH3T3 cells transfected with the indicated GFP-NPM-ALK plasmids (0.5 m of each NPM-ALK vector and 0.5 mg of carrier DNA pcDNA [Invitrogene] ). The morphology and the number of transformed foci were evaluated after 2 weeks of culture, as previously described (Bai et al., 1998) . Src inhibitor PP2 was purchased from Calbiochem.
Flow cytometry
Flow cytometry was performed as described (Chiarle et al., 1999) . Brie¯y, cells were washed once with PBS and resuspended in staining buer (10 mM HEPES pH 7.4, 140 mM NaCl, 2.5 mM CaCl) with 5 ml of AnnexinV-PE (AnnexinV kit, Roche). After 15 min of incubation, in the dark, cells were directly analysed in the FACScan. (BectonDickinson). Cells were evaluated using a CellQuest Program (Becton-Dickinson). Data were plotted using a histogram algorithm, in which the intensities of Annexin V positive cells were represented in a log 10 scale.
Constructs
Somatically mutated NPM-ALK constructs were generated using speci®c oligonucleotide primers by using a sitedirected mutagenesis kit (Statagene). Truncated constructs were derived through a recombinant PCR approach and speci®c overlapping primers. The truncated constructs T1-498, T1-458, T1-458Y191FY445F, T1-436 and T1-363 were tagged using a Flag sequence at the COOH terminus. Tagging was necessary because the truncated proteins lost the ALK peptide which is speci®cally recognized by the rabbit anti-ALK antibody. Automated DNA sequencing was performed on all constructs to con®rm the presence of the mutations.
Western blot analysis and immunoprecipitation
Frozen tissue samples and cell from cell lines were lysed (20 mM Tris-HCl pH 8, 150 mM NaCl, 1% Triton X-100, 5 mM EDTA, 1 mM Na 3 VO 4 and 1 mM PMSF) and spun. At least 10 mg of total protein lysates were electrophoresed in SDS ± PAGE gel and transferred onto nitrocellulose membranes. The ®lters were ®rst blocked (5% low fat milk in PBS with 0.1% Tween 20; 1 h at RT) and then incubated with anti-Stat3 (1 : 1000, Zymed), anti-phospho-Stat3 (1 : 1000, New England Biolabs), anti-Stat5 (1 : 1000, Zymed), antiphospho-Stat5 (1 : 1000, New England Biolabs), anti-ALK (1 : 4000, Zymed), anti-Cyclin D1 (1 : 10, from Dr M Pagano), anti-Cdk2 (1 : 500, rabbit polyclonal from Dr M Pagano), anti-phospho-Akt (1 : 1000, Calbiochem), anti-b-tubulin (1 : 2000, Sigma), anti-Bcl-x L (1 : 250, Santa Cruz Biotechnology), anti Mcl-1 (1 : 500, Dako) and anti-survivin (5 ml/ml, from Dr D Altieri). Following three washes, ®lters were reacted with HRPO-conjugated goat anti-mouse or with HRPO-conjugated goat anti-rabbit (1 : 2000, Amesham, 1 h at RT). Detection of immunocomplexes was performed with chemiluminescence (ECL, Amersham). For immunoprecipitation assays lysates were ®rst precleared with protein Gagarose beads and then incubated with the primary antibody (1 h 48C) followed by protein G beads (1 h 48C). Immunocomplexes were then precipitated, washed, boiled and electrophoresed. Detection of the blotted proteins was performed as described above.
Luciferase assay NIH3T3 cells were co-transfected with the NPM-ALK, K210R NPM-ALK, v-src and Stat3b (1 mg of plasmid each) in association with the Bcl-x L promoter constructs (Bcl-x L 1.2 and 0.6, 0.5 mg, each plasmid, Catlett-Falcone et al., 1999) driving the expression of the luciferase gene. After transfection (36 h) cells were lysed and the luciferase assay was performed using a luciferase detection kit (Promega). The eciency of transfection was normalized by GFP expression.
